Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641089 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
A Phase 3 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06641089: Recruiting Phase 3 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
NCT06641089 is a Phase 3 study of Arthritis, Psoriatic that is actively recruiting participants, run by MoonLake Immunotherapeutics. The registered enrollment target is 600 participants, above the 539-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06641089, a Phase 3 study of Arthritis, Psoriatic, is actively recruiting participants, sponsored by MoonLake Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Primary Outcome
Proportion of participants achieving ACR50
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sonelokimab
- DRUG Risankizumab
Study Locations (20)
Arizona
- Clinical Site - Avondale
- Clinical Site - Chandler
- Clinical Site - Flagstaff
- Clinical Site - Mesa
- Clinical Site - Phoenix
- Clinical Site - Scottsdale
- Clinical Site - Tucson
California
- Clinical Site - La Jolla
- Clinical Site - Pomona
- Clinical Site - San Diego
- Clinical Site - Santa Monica
- Clinical Site - Thousand Oaks
- Clinical Site - Upland
Florida
- Clinical Site - Avon Park
- Clinical Site - Clearwater
- Clinical Site - Hialeah
- Clinical Site - Miami Gardens
- Clinical Site - Tampa
- Clinical Site - Zephyrhills
Arkansas
- Clinical Site - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 3 |
What NCT06641089 shows while recruiting
NCT06641089 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 539-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06641089 names 20 study sites across 4 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06641089 about?
NCT06641089 is a clinical study titled "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response". This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
What is the current status of trial NCT06641089?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2024-10-15. Estimated completion is 2027-01-15.
What conditions does trial NCT06641089 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT06641089?
The interventions under investigation include: Placebo (DRUG), Sonelokimab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06641089?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641089 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06641089's enrollment target sits among peer trials
600 6th of 16 higher than 11 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI